We are live on ! Find out more
AAPG

Ascentage Pharma
AAPG

7 hedge funds and large institutions have $722K invested in Ascentage Pharma in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.05% → 0.03% (-0.02%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

42% less funds holding

Funds holding: 12 → 7 (-5)

42% less capital invested

Capital invested by funds: $1.25M → $722K (-$531K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
7
Holders Change
-5
Holders Change %
-41.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$8.49K
2
TRCT
Tower Research Capital (TRC)
New York
+$7.09K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$255K
2
UBS Group
UBS Group
Switzerland
-$101K
3
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$66.8K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.5K
5
XC
XY Capital
Hong Kong
-$15.1K

AAPG Hedge Fund Activity: Q1 2026 in Review

7 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q1 2026, worth a combined $722K — down 42% from $1.25M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of AAPG and 0 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $8.49K. The largest seller was Citadel Advisors, exiting entirely with an estimated $255K sold.

  • 7 institutional investors held Ascentage Pharma (AAPG) as of Q1 2026, down from 12 in Q4 2025.
  • Funds reported $722K of Ascentage Pharma stock for Q1 2026, down 42% quarter-over-quarter.
  • 0 funds opened new Ascentage Pharma positions in Q1 2026 and 5 closed out, a net change of -5 holders.
  • The largest Ascentage Pharma buyer in Q1 2026 was Morgan Stanley, an estimated $8.49K added.
  • The largest Ascentage Pharma seller in Q1 2026 was Citadel Advisors, an estimated $255K sold.

Based on aggregated 13F filings for Q1 2026.